Pharmac has been in the news a fair bit recently. It pops up from time to time, and this time it’s because of our negotiations with the USA over the Trans-Pacific Partnership or TPP, a Pacific free trade agreement.
There are concerns about Pharmac’s accountable, transparency and openness to innovative medicine, according to Medicines New Zealand, an association that represents companies engaged in research, development, manufacture and marketing of prescription medicines.
An association with an obvious bias. However Medicines New Zealand did have an interesting opinion piece in the Dominion Post recently which raised one or two valid concerns about the drug-buying agency. But on the whole I think Pharmac does a pretty good of allocating scarce resources.
Last week I a listened to an interview that had Pharmac squarely in the middle. Allyson Lock has Pompe, a degenerative, neuromuscular condition. It sounds like a truly horrible disease , and there is no cure, only treatment. But the treatment is a drug that Pharmc won’t fund. Allyson said that she has been before a Pharmac committee to put her case to get the drug funded under special provisions. And she says that at that meeting Pharmac put it to her that if they fund it for her, it will be at someone else’s expense.
I find that ‘guilt trip’ appalling but sadly it’s not the first time I’ve heard of professionals in the health system using it. And though it’s an awful thing to say to anyone – and shouldn’t be said to someone in that situation, it is what happens. That’s because we have to ration our health resources. It’s not just New Zealand, every country rations health services in some way.
In the USA, for example, it’s rationed by your ability to pay. There, you can probably have any drug you need, so long as you can afford to pay for it. Pharmac limits the range and availability of drugs to keep within its budget and provide a service that caters to the whole population, not just the rich. Neither system seems fair, but in my opinion, one system is much fairer than the other.
Two years ago I was part of a group that looked at a fairer way to allocate equipment to people with disabilities. We found that in the current system, some decisions are made subjectively because there isn’t a good mechanism for assessors to objectively judge one case against another. They are sometimes swayed by emotional factors, and this usually doesn’t lead to good decisions.
We saw examples where equipment was purchased and then wasn’t used because it was too complicated or difficult to use, or it didn’t actually meet the intended need. What a waste of tax-payer money.
I understand a new system is being piloted which, if fully implemented, will result in better decision-making. Will it be fair? The outcome won’t always be fair, because with limited money available, someone will always miss out. But the process to get there will be much fairer. Which brings me back to Pharmac.
There’s much more to the Allyson’s story and The New Zealand Organisation for Rare Disorders (NORD) is advocating on behalf of her and other people who miss out on life-saving drugs because their diseases is so rare. You can read an article about that here.
NORD’s chairman John Foreman said in the article that “fairness and equity should be part of the whole decision-making process.” He’s right, and that ‘s why I found it rather disconcerting hearing Allyson’s case put to Pharmac Medical Director Dr Peter Moodie in such emotional terms. Because sad as it is, there are other people in New Zealand in equally distressing situations.
Some people will inevitably always miss out. Has Pharmac got its decision-making processes right? I don’t know the answer to that, and there probably is room for improvement. One day it might be you or me who misses out on a life-saving drug, and we won’t think it’s fair.
Or elsewhere in the health system we’ll be denied an operation, a treatment, a mobility aid, a service …. I hope if it’s me or one of my family, that I would be able to accept it if I know the process that led to that decision was an equitible one, one where emotions are left at the door. They have to be if the system is going to be fair to everyone.
The irony is that what Allyson Lock was told is true - if Pharmac funds the drug she so badly needs, someone else will miss out. And sadly that’s not likely to change, whatever internal changes Pharmac makes. Because Pharmac will still have to work within its budget, and with the financial situation the country is in, that’s not likely to change very much either.
It’s not something any of us want to hear, but someone always misses out when it comes to health rationing.